Zacks Investment Research·1d ago
NVAX Stock Falls 8% Despite Q3 Earnings & Sales Beat, Costs DeclineNovavax shares fall 8% despite Q3 earnings and revenue beat as costs decline, while a Sanofi milestone drives a sharp increase in its 2026 outlook.
Novavax's revenue has collapsed 91.5% from its 2025Q1 peak of $666.7M to $56.7M in 2026Q2, reflecting the boom-bust nature of COVID vaccine demand.
Price trend, volume and key moving averages
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.19+45.1% vs -$0.35 | $68M+35.4% vs $50M |
Q3 2026 Aug 6, 2026 | -$0.32+15.8% vs -$0.38 | $57M+8.0% vs $53M |
Q2 2026 May 6, 2026 | -$0.06+76.0% vs -$0.25 | $140M+74.8% vs $80M |
Q1 2026 Feb 26, 2026 | $0.11+116.7% vs -$0.66 | $147M+63.8% vs $90M |
Novavax shares fall 8% despite Q3 earnings and revenue beat as costs decline, while a Sanofi milestone drives a sharp increase in its 2026 outlook.
Novavax NASDAQ: NVAX raised its 2026 revenue framework after partner Sanofi began a late-stage trial of a combination influenza and COVID-19 vaccine in Europe, triggering a $125 million milestone payment for the vaccine technology company.
Novavax, Inc. (NVAX) Q3 2026 Earnings Call Transcript
Novavax (NVAX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to a loss of $0.62 per share a year ago.
Benchmark NVAX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Novavax, Inc. (NVAX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.78 | $1.77B | -23.17 | 64.69% | -18.64% | — | — | |
| $254.19 | $100.86B | -39.19 | -39.23% | -110.46% | -37.62% | — | |
| $87.51 | $21.98B | -13.43 | 0.2% | -61.28% | -8.06% | — | |
| $29.39 | $167.51B | 41.91 | -1.65% | 6.34% | 4.58% | 5.85% | |
| $47.04 | $112.95B | 24.24 | 5.49% | 8.19% | 5.81% | 5.23% | |
| $50.33 | $100.84B | 17.69 | 4.11% | 12.96% | 23.31% | 3.23% |
Novavax, Inc. (NVAX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Novavax, Inc. (NVAX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 23, 2026·SEC
May 6, 2026·SEC
Get notified when NVAX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Novavax, Inc. (NVAX) stock FAQ — growth, dividends, profitability & financials explained
Novavax, Inc. (NVAX) reported $411.6M in revenue over the trailing twelve months. Revenue was $1.12B in fiscal year 2025. That is 1123379% more than the $0.1M of fiscal year 1996.
Novavax, Inc. (NVAX) revenue fell by 61.3% over the trailing twelve months, compared with the twelve months before.
No. Novavax, Inc. (NVAX) reported a net loss of $76.7M over the trailing twelve months.
Novavax, Inc. (NVAX) had negative free cash flow of $244.6M over the trailing twelve months.
